^
    Back
    Association details:
    Biomarker:PAX5-JAK2 fusion
    Cancer:B Acute Lymphoblastic Leukemia
    Drug:CHZ868 (JAK2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2022
    Title:

    150 Novel Drugs to Target JAK2 Rearrangements in Pediatric Acute Lymphoblastic Leukemia

    Published date:
    11/03/2022
    Excerpt:
    Finally, we demonstrated the in vivo efficacy of CHZ868 in PAX5::JAK2, ATF7IP::JAK2 and ZEB2::JAK2 patient-derived- xenografts.
    DOI:
    https://doi.org/10.1182/blood-2022-169437
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2021
    Title:

    Targeting JAK2 Gene Rearrangements with a Novel Kinase Inhibitor in a Preclinical Model of Pediatric Acute Lymphoblastic Leukemia

    Published date:
    11/04/2021
    Excerpt:
    Finally, we demonstrated the in vivo efficacy of CHZ868 in patient derived xenograft model in presence of PAX5-JAK2 fusion...CHZ868 is a promising candidate for treatment of BCP-ALL carrying JAK2 fusions, showing high efficacy and specificity, both ex vivo and in vivo.
    DOI:
    10.1182/blood-2021-152270